Building Retained Earnings and Preparing for Growth Investment
First written in FY2016. 10 of 12 entries say "Restated". Latest entry: 2026-06-10.
The whole theme swung hardest in 2020: 2 of 18 companies on the "Worse" side.
17 other companies' latest entry also says "Restated".
- 2026-06-10RestatedEarnings presentation
「海外事業拡充への成長投資の原資を確保するため、前出の戦略による増収と、高稼働率の維持とコスト管理を徹底し、一株当たり利益の持続的成長を確保」
海外事業拡充の成長投資に向け、増収、高稼働率、コスト管理及び一株当たり利益の成長を組み合わせる方針が再確認された。 - FY2024RestatedAnnual report
「The Group will use retained earnings for essential growth investment needed for future business development and meet shareholders’ expectations by enhancing corporate value through medium- to long-term growth.」
The policy of using retained earnings for growth investment to enhance corporate value has been reaffirmed. - FY2020RestatedAnnual report
「The Group will build retained earnings through rigorous budget-versus-actual and cost management and prepare for essential growth investments needed for future business development, including securing talented personnel and establishing a framework for international joint clinical trials.」
The policy of using budget and cost management and retained earnings as sources of funds for future investment in human resources and an international joint clinical trial framework remains in place. - FY2019RestatedAnnual report
「Funding needs for investment comprise funds for acquisitions through M&A and other purposes as essential growth investment needed for future business development.」
The policy of using retained earnings for future growth investment remains in place, with acquisitions through M&A and other transactions explicitly cited as examples of growth investment. - FY2018RestatedAnnual report
「The Group will build retained earnings through rigorous budget-versus-actual and cost management and prepare for essential growth investments needed for future business development, including securing talented personnel and establishing a framework for international joint clinical trials.」
The policy of using budget and cost management and retained earnings as sources of funds for future investment in human resources and an international joint clinical trial framework remains in place. - FY2018-Q3RestatedAnnual report
「Profit declined because personnel expenses, rent, and other costs increased as planned, following the hiring of personnel and relocation of the Tokyo office at the beginning of the fiscal year to increase floor space and staffing in line with the order plan, which included the projects described above that had already been awarded in the previous fiscal year but had not started.」
Upfront investment for future business expansion has been implemented, including hiring personnel based on the order plan and expanding and relocating the Tokyo office. No change in the policy concerning retained earnings or growth investment has been disclosed. - FY2018-Q2RestatedAnnual report
「Cost of sales for the six months ended 30 September was ¥2,629 million, up 21.8% year on year, mainly as a result of increasing staffing in preparation for growth in the number of outsourced clinical trial projects.」
Upfront investment in human resources to prepare for growth in the number of contracted clinical trials continues, appearing as an increase in expenses. No material change in the policy concerning retained earnings or growth investment has been disclosed. - FY2018-Q1RestatedAnnual report
「Cost of sales for the three months ended 30 June was ¥1,444 million, up 19.8% year on year, mainly as a result of higher personnel expenses arising from front-loaded investment in personnel and costs associated with relocating the Tokyo office, among other factors.」
Upfront investment in human resources for future business expansion continues, but no change in the policy concerning retained earnings or sources of growth investment has been disclosed. - FY2017RestatedAnnual report
「The Group aims to secure high profitability by accepting CRO projects centered on highly profitable monitoring services and other operations, while building retained earnings through rigorous budget-versus-actual and cost management. It will use these funds to prepare for essential growth investments needed for future business development, including securing talented personnel and establishing a framework for international joint clinical trials.」
The policy of using highly profitable operations, budget and cost management, and retained earnings as sources of funds for future investment in human resources and an international joint clinical trial framework remains in place. - FY2017-Q3RestatedAnnual report
「Cost of sales for the nine months ended 31 December was ¥3,402 million, up 9.4% year on year, mainly as a result of increasing staffing in preparation for growth in the number of outsourced clinical trial projects.」
Upfront investment in human resources to prepare for growth in the number of contracted clinical trials continues to appear as an increase in cost of sales. - FY2017-Q2AdvancedAnnual report
「Operating profit was ¥1,120 million, down 1.0%, as increases in cost of sales, selling, general and administrative expenses from upfront investment in human resources, particularly in Japan, and the reduced yen-denominated contribution from overseas subsidiaries due to the stronger yen weighed on earnings.」
Upfront investment in human resources in Japan for future business expansion was implemented, appearing as increases in cost of sales, selling expenses and general and administrative expenses. - FY2016First statedAnnual report
「The Group aims to secure high profitability by accepting CRO projects centered on highly profitable monitoring services and other operations, while building retained earnings through rigorous budget-versus-actual and cost management. It will use these funds to prepare for essential growth investments needed for future business development, including securing talented personnel and establishing a framework for international joint clinical trials.」
The Group positions profitability, budget and cost management, and retained earnings as sources of funds for growth investment in human resources and international expansion.